N -[ 11 CH 3 ]Dimethylaminoparthenolide (DMAPT) uptake into orthotopic 9LSF glioblastoma tumors in the rat

Penthala, Narsimha Reddy; Janganati, Venumadhav; Alpe, Terri; Apana, Scott M.; Berridge, Marc S.; Crooks, Peter A.; Borrelli, Michael J.

doi:10.1016/j.bmcl.2016.11.015

Cited by 5 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the anticancer potential of PN has attracted great attention. PN, and its 1000-fold more soluble in water synthetic derivative, dimethylamino-parthenolide (DMAPT; Figure 1 ), were subjects of many preclinical in vitro and in vivo studies, performed on cancer cells from hematological malignancies and solid tumors [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ].…”

Section: Introductionmentioning

confidence: 99%

Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies

Sztiller-Sikorska¹,

Czyż²

2020

Pharmaceuticals

View full text Add to dashboard Cite

Primary and acquired resistance of cancer to therapy is often associated with activation of nuclear factor kappa B (NF-κB). Parthenolide (PN) has been shown to inhibit NF-κB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. Multimodal therapies that include PN or its derivatives seem to be promising approaches enhancing sensitivity of cancer cells to therapy and diminishing development of resistance. A number of studies have demonstrated that several drugs with various targets and mechanisms of action can cooperate with PN to eliminate cancer cells or inhibit their proliferation. This review summarizes the current state of knowledge on PN activity and its potential utility as complementary therapy against different cancers.

show abstract